Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Umer Raffat | Evercore ISI | 6 | 50% |
| Chris Schott | JPMorgan | 6 | 17% |
| Vamil Divan | Guggenheim | 5 | 0% |
| Jim Shin | Deutsche Bank | 5 | 0% |
| Geoff Meacham | Citigroup | 5 | 0% |
| Daina Graybosch | Leerink Partners | 5 | 0% |
| Akash Tewari | Jefferies | 5 | 20% |
| Alex Hammond | Wolfe Research | 4 | 0% |
| Mohit Bansal | Wells Fargo | 4 | 25% |
| Steve Scala | TD Cowen | 3 | 67% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| JPMorgan | 1 | 6 | 17% |
| Evercore ISI | 1 | 6 | 50% |
| Citigroup | 1 | 5 | 0% |
| Guggenheim | 1 |
| 5 |
| 0% |
| Jefferies | 1 | 5 | 20% |
| Deutsche Bank | 1 | 5 | 0% |
| Leerink Partners | 1 | 5 | 0% |
| Bank of America | 2 | 4 | 50% |
Merck delivered revenue of $15.5 billion with KEYTRUDA at $7.0 billion facing initial biosimilar competition in select ex-U.S. markets, while WINREVAIR grew to $830 million in the quarter and GARDASIL showed early recovery signs with China shipments improving sequentially. Management reiterated FY2026 guidance of $63.5-64.5 billion in revenue and $8.55-8.70 in non-GAAP EPS, while advancing the subcutaneous KEYTRUDA formulation toward approval and highlighting positive Phase 3 data for sacituzumab govitecan in bladder cancer.
Innovation & R&D | Competitive Dynamics | Regulation Policy | Product Launch | Demand | M&A | Guidance Reliability | Revenue Growth | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 4 | 2 | 3 | 1 | 5 | 1 | 2 | 1 |
| 2025Q1 | 2 | 1 | 5 | 2 | 2 | 2 | ||
| 2025Q2 | 6 | 3 | 3 | 3 | 1 | 2 | 1 | |
| 2025Q3 | 5 | 2 | 3 | 4 | 1 | 1 | 1 | 3 |
| 2025Q4 | 8 | 4 | 1 | 3 | 1 | 1 | 1 | 1 |
| 2026Q1 | 11 | 7 | 2 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Innovation & R&D | 4 | 2 | 6 | 5 | 8 | 11 |
| Competitive Dynamics | 2 | 1 | 3 | 2 | 4 | 7 |
| Regulation Policy | 3 | 5 | 3 | 3 | 1 | 2 |
| Product Launch | 1 | 3 | 4 | 3 | ||
| Demand | 5 | 2 | 1 | 1 | 1 | |
| M&A | 1 | 2 | 2 | 1 | 1 | 2 |
| Guidance Reliability | 2 | 2 | 1 | 1 | 1 | |
| Revenue Growth | 1 | 3 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
MRK Merck & Co., Inc. | 7 | +4.3% | |
| ABBV AbbVie | 9 | +12.4% | |
| AMGN Amgen Inc. | 8 | +5.8% | |
| BIIB Biogen | 4 | +1.9% | |
| BMY Bristol Myers Squibb | 4 | +2.6% | |
| GILD Gilead Sciences | 8 | +4.4% | |
| JNJ Johnson & Johnson | 7 | +10.1% | |
| LLY Lilly (Eli) | 10 | +55.5% | |
| PFE Pfizer | 5 | +5.4% |